Curaleaf Holdings Inc (CURA.TO) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Curaleaf Holdings Inc (CURA.TO)

14.16

+0.53 (3.89%)

as of Jun 26, 2026, 8:00:00 pm Market Open.

119 watching

Investor Insights

Jun 27, 2026, 12:00 am

This summary was created by AI, based on 6 opinions in the last 12 months.

Curaleaf Holdings Inc (CURA-T) is currently experiencing significant volatility, heavily influenced by the political landscape surrounding cannabis legalization in the U.S. Experts note that while excitement over potential rescheduling of cannabis could lead to reduced tax burdens and improve cash flow, predicting the timing of such changes remains uncertain. The company is seen as a leader in the cannabis sector, competing strongly with other key players like Trulieve (TRUL). There is a consensus among analysts that while both CURA and its peers may retain their current market positions without rescheduling, their stock prices may trend toward previous lows. Overall, the sector has shown improvement with healthier balance sheets, and many believe CURA is undervalued, offering room for growth, but it still carries inherent risks due to its reliance on regulatory changes.

Consensus

Volatile

Valuation

Undervalued

Similar

Trulieve,TRUL

TOP PICK

Operates entirely in the US. Largest marijuana producer in the world by sales. Vertically integrated. Growing quickly organically and by acquisition. Regulatory tailwind. Democrats taking Senate increase likelihood of legislative reform. Great company, lots of growth runway. No dividend. (Analysts’ price target is $19.98)

BUY

It's the largest US MSO (multi-state operator) in several U.S. states. They've built up a small private company over two years, then went public. MSOs are capturing more attention and capital flows.

TOP PICK

Operates entirely in US, with 10x the market. Canadian red tape has made it difficult for regulated companies to take market share from black market. Whereas US market is undersupplied. Vertical integration and geographic diversity are part of its strategy. Good management. No dividend. (Analysts’ price target is $17.47)

HOLD

He finds it fascinating that cannabis is still illegal in the US, but is deemed essential during the pandemic. He thinks this will lead to relaxed regulations in the future. The company generates increasing revenue and positive cash flow -- only a handful of US cannabis companies do. He thinks it will be a dominant player in years to come in the space.

BUY

CURELF-N vs. CL-X. He really made a focus on the US for cannabis. He thinks the US MSOs have a tremendous amount of room to go. CURELF-N is one of the leaders. CL-X just did a deal in California, which is one of the biggest markets out there. He likes both of them. They are both leaders.

Showing 31 to 35 of 35 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Kevin Simpson

Capital Wealth Planning

Bryn Talkington

Requisite Capital Management

Andrey Omelchak

LionGuard Capital Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Curaleaf Holdings Inc (CURA.TO)